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ABSTRACT
Cysteinyl leukotrienes (CysLTs: leukotrienes C4, D4, and E4) have long been implicated in the pathogenesis of
asthma and several allergic diseases. LTE4 has been identified as a major metabolite of LTC4, and urinary
LTE4 (U-LTE4) is considered as the most reliable analytic parameter for monitoring the endogenous synthesis
of CysLTs. From recent studies on the U-LTE4 associated with adult stable asthma we identified four factors for
hyperleukotrieneuria, namely, aspirin intolerance, eosinophilic nasal polyposis (ENP), vasculitis, and severe
asthma. In ENP, there is prominent infiltration of eosinophils in the sinus and polyp tissues, which is linked to
adult asthma and aspirin sensitivity, and ENP is the most important factor for the overproduction of CysLTs in
asthmatics. We also demonstrated that anaphylaxis and eosinophilic pneumonia (EP) are associated with a
marked increase in the U-LTE4 concentration. Under these disease conditions, U-LTE4 may be one of the can-
didate biomarkers. Moreover, the changes in U-LTE4 concentrations may provide valuable information con-
cerning therapeutic targets.
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STABLE ASTHMA WITH HYPERLEUKOT-
RIENEURIA
Leukotrienes (LTs) are downstream products of the
metabolism of cell or nuclear membrane phospholip-
ids. In certain inflammatory cells such as eosinophils,
mast cells, and other inflammatory cells, degradation
to arachidonic acid (AA) by phospholipase A2 occurs
at the nuclear membrane, which indicates the bio-
logic functions of the LTs once they are formed.1-4 5-
lipoxygenase activation at the cytoplasmic or nuclear
membrane then leads to the production of an unsta-
ble intermediate known as leukotriene A4 (LTA4),
which can be further metabolized, depending on cell
type, to LTB4 or the cysLTs (LTC4, LTD4, and LTE4).
LTC4 synthase metabolizes LTA4 to LTC4 via glu-
tathione transferase. LTC4 is then rapidly metabo-
lized to LTD4 and LTE4 through the enzymes gamma-
glutamyl transpeptidase and a dipeptidase. LTC4 and
LTD4 both have very short half-lives, whereas LTE4
appears to be the most stable of the three, with the
longest half-life.5
LTE4 has been identified as a major metabolite of
LTC4; urinary LTE4 (U-LTE4) has been considered as
the most reliable analytic parameter for monitoring
the endogenous synthesis of CysLTs.6 We previously
described an efficient procedure for the precise quan-
titation of LTE4 in a small volume of urine, which was
achieved mainly by the use of an Empore extraction
disk cartridge.7 Asano et al. reported that no system-
atic variation in urinary LTE4 excretion rates over the
course of a day was observed in either normal sub-
jects or patients with stable asthma.8 Even under a
clinically stable condition, the U-LTE4 concentration
in patients with aspirin-intolerant asthma (AIA) is sig-
nificantly higher than that in patients with aspirin-
tolerant asthma (ATA) (Fig. 1).9-12 We evaluated the
clinicopathological factors associated with the in-
crease in U-LTE4 concentration in asthmatics and
have confirmed that the U-LTE4 concentration in AIA
patients is significantly higher than those in ATA pa-
tients. Depending on asthma severity, ATA patients
with severe asthma and AIA patients with poor pul-
monary function showed a significant increase in U-
LTE4 concentration, but the extent of increase was
not large (Fig. 2).11 Moreover, we have demonstrated
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Fig. 1 Basal levels of urinary LTE4 in patients with aspirin-
intolerant asthma (AIA) and patients with aspirin-tolerant 
asthma (ATA). Horizontal bars indicate geometric means.　
＊p＜0.001 compared with the control group; ＊ ＊p＜0.0001 
compared with the ATA group. (Adapted from Kawagishi et 
al.12)
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Fig. 2 Urinary LTE4 concentration in patients with aspirin-intolerant 
asthma (AIA) and patients with aspirin-tolerant asthma (ATA) classified ac-
cording to clinical severity of asthma. U-LTE4 concentration is expressed 
by using the log scale. Patients with ATA and patients with AIA are denoted 
by closed square (■) and closed circle (●), respectively. The doted line 
indicates the mean level of U-LTE4 in healthy control subjects. ＊ U-LTE4 
concentration in patients with ATA with diferent clinical asthma severity lev-
els were compared by using the Kruskal-Walis test. (Adapted from Higashi 
et al.11)
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for the first time that nasal polyposis is one of the
most important factors that indicate hyperleukot-
rienuria.11 Recently, we have determined another
clinicopathological factor for hyperleukotrienuria in
patients with adult asthma. Churg-Strauss syndrome
(CSS) is characterized by the presence of asthma,
eosinophilia, and small-vessel vasculitis with granu-
loma.13,14 The natural history of CSS is, first, the ap-
pearance of eosinophilic rhinosinusitis, followed sev-
eral years later by the development of difficult asthma
with marked peripheral blood eosinophilia, and fi-
nally the development of systemic vasculitis.13 We
have demonstrated that the U-LTE4 concentration is
elevated in the acute phase of CSS. However, the U-
LTE4 concentration significantly increases in patients
with not only eosinophilic vasculitides, including
CSS, but also noneosinophilic vasculitides (Fig. 3).14
CysLTs OVERPRODUCTION IN ACUTE
ASTHMA
1) SPONTANEOUS ATTACK
In acute asthmatics, the urinary excretion of LTE4
was significantly higher on admission with an asthma
attack, and returned to control levels when the pa-
tient’s conditions improved. However, the increased
level of U-LTE4 was only 2-fold higher than that of
healthy controls (Fig. 4).15 Oosaki also reported that
there is a significant correlation between changes (%)
in urinary eosinophil protein X (EPX), which may
originate from eosinophil activation, and those in uri-
nary LTE4 during the spontaneous attack state.16
Moreover, Green et al. reported that the decreases in
FEV1 are significantly correlated to U-LTE4 concen-
trations in patients with acute exacerbation of
asthma.17 Tanaka and his colleages found that the U-
LTE4 concentration at night significantly increased in
Hyperleukotrieneuria in Asthma and Inflammation
Allergology International Vol 57, No4, 2008 www.jsaweb.jp 315
Fig. 3 Urinary LTE4 (A) and EDN (B) concentration in 
each group. Urinary concentrations are expressed by using 
the log scale. Horizontal bars indicate medians. ＊ p＜0.05; 
† p＜ 0.01. HC: healthy control, RA: rheumatoid arthritis, 
VD: non-eosinophilic vasculitis, CSS: Churg-Strauss 
syndrome. (Adapted from Higashi et al.14)
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Fig. 4 Change in urinary LTE4 concentration before and after treatment in patients with 
the spontaneous asthma atack. ＊p＜0.05; ＊ ＊p＜0.01; ＊ ＊ ＊p＜0.01 compared with im
proved state. (Adapted from Oosaki et al.15)
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patients with nocturnal asthma.18 These findings sug-
gest that systemic CysLTs overproduction during a
spontaneous attack is mainly caused by eosinophils,
and that it is closely related to human airflow limita-
tion.
2) ALLERGEN-INDUCED ASTHMATIC REAC-
TION
The urinary LTE4 concentration increases during the
first 3h after allergen inhalation in atopic patients.19,20
However, no significant increase is observed in the
late phase during allergen-induced bronchoconstric-
tion (Fig. 5).19 Moreover overproduction of CysLTs
in allergen-induced asthma was found to be not asso-
ciated with an increased concentration of LTB4 glucu-
ronide in urine.19 Very recently, we have quantified
lipid mediators in exhaled breath condensate (EBC)
and their corresponding urinary metabolites before
and after allergen inhalation. In the patients with
allergen-induced early asthmatic responses (EARs),
the decreased percentage in FEV1 significantly corre-
lated with the increase in CysLTs concentration in
EBC but not with the increase in U-LTE4 concentra-
tion after allergen inhalation (Fig. 6).21 There was a
significant correlation between increased concentra-
tions of CysLTs and PGD2 in EBC collected in pa-
tients with EARs after allergen inhalation. However,
the increase in urinary 9α, 11β-PGF2 (metabolite pre-
sumably related to mast cell activation.22), concentra-
tions did not correlate with either the increase in
PGD2 concentration in EBC or that in LTE4 concen-
tration in urine.21 These results suggest that (1) hu-
man EARs may be mainly induced by CysLTs gener-
ated by pulmonary mast cells and (2) urinary LTE4
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Fig. 6 In the patients with alergen-induced early asthmatic responses (EARs), the de-
creased percentage in FEV1 significantly corelated with the increase in CysLT concentra-
tion in EBC (A) but not with the increase of Urinary LTE4 concentration (B) after alergen 
inhalation. (Adapted from Ono et al.21)
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Fig. 7 Urinary leukotriene E4 concentration (pg/mg of cre
atinine) in each group. Healthy control subjects, seasonal al
lergic rhinitis patients with mild or no nasal blockage, 
seasonal alergic rhinitis patients with severe nasal block
age, and patients with both seasonal alergic rhinitis (SAR) 
and asthma (BA). (Adapted from Higashi et al.26)
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and PGD2 metabolite may not be direct indicators of
eicosanoid production in the airway.
HYPERLEUKOTRIENURIA IN SEASONAL
ALLERGIC RHINITIS (SAR)
CysLTs have been reported to play a primary role in
the induction of nasal blockage associated with aller-
gic rhinitis, with limited effect on other rhinitis symp-
toms.23-25 We demonstrated for the first time that the
basal U-LTE4 concentration is significantly higher in
SAR patients with severe nasal blockage than in those
with mild or no nasal blockage and in healthy control
subjects.26 More interestingly, there was no signifi-
cant difference in the U-LTE4 concentration between
the patients with both SAR and asthma and SAR pa-
tients with severe nasal blockage (Fig. 7).26 There is
a significant correlation between U-LTE4 and 9α11
βPGF2 concentrations. On the other hand, there is no
significant correlation between U-LTE 4 and
eosinophil-derived neurotoxin (EDN) concentra-
tions.26 These results indicate that nasal blockage
may be induced by the overproduction of CysLTs
generated by mast cells rather than by eosinophils in
the nasal cavity of SAR patients.
ROLE OF CysLTs IN THE PATHOGENESIS
OF NASAL POLYPOSIS
Nasal polyps are edematous semitranslucent masses
in the nasal and paranasal cavities, mostly originating
from the mucosal linings of the sinuses and prolaps-
Fig. 5 Change in urinary LTE4 concentration before and 
after alergen inhalation in patients with mite-sensitive 
asthmatics. (Adapted from Mita et al.19)
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Fig. 8 Urinary LTE4 concentration in aspirin-tolerant asthma (ATA) and 
aspirin-intolerant asthma (AIA) patients with eosinophilic nasal polyposis 
(ENP) and those with normal sinuses. Urinary LTE4 concentration is ex-
pressed by using the log scale. The horizontal bars indicate medians. 
(Adapted from Higashi et al.11)
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Fig. 9 A significant decrease in urinary LTE4 concentration between before and after the 
endoscopic sinus surgery without changing medication. The horizontal bars indicate 
medians. (Adapted from Higashi et al.11)
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ing into the nasal cavities. Eosinophilic nasal poly-
posis (ENP), in which there is prominent infiltration
of eosinophils and submucosal edema, is linked to
comorbidities such as nonatopic asthma, adult-onset
asthma, and aspirin intolerance, or may represent a
part of a systemic disease such as CSS. Despite sinus
surgery or intensive steroid therapy, the recurrence
rate of ENP in patients with asthma is very high, and
the pathogenesis of ENP has not been clarified.27
For the first time, we found that the U-LTE4 con-
centration is significantly high even in ENP patients
without aspirin sensitivity (Fig. 8).11 We then con-
firmed the changes in U-LTE4 concentration after en-
doscopic sinus surgery without changing the medica-
Taniguchi M et al.
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Fig. 10 Changes in urinary LTE4 and 9α, 11β-PGF2 con-
centrations in anaphylactic patients after provocation test. 
＊p＜0.01, ＊ ＊p＜ 0.001 compared with baseline. (Adapted 
from Ono et al.37)
pg/mg-cr
0
200
400
600
800
1000
Pre
(baseline)
0―3 3―6 6―9 9―24 hr
＊
＊＊
＊
LTE4
9α11βPGF2
n ＝ 10
median (interquartile range) 
Fig. 11 Urinary LTE4 concentrations in 19 eosinophilic pneumonia (EP) sub
jects, 18 patients with exacerbations of bronchial asthma (BA), 15 patients with sta
ble BA and 15 healthy controls (HC). Horizontal bars indicate medians. cr: 
creatinine. #: p＝ 0.036; ¶: p＝ 0.042; ＊ ＊ ＊ :p＜ 0.001. (Adapted from Ono et 
al.41)
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tion. We demonstrated that U-LTE4 concentrations
significantly decreased after the sinus surgery in both
AIA and ATA patients (Fig. 9).11 Steinke et al. re-
ported that the CysLTs concentrations in ENP tissues
are significantly higher than those in noneosinophilic
nasal polyp tissues.28 They also demonstrated that
the presence of CysLTs in ENP tissues is associated
with an increased expression level of LTC4syntase
mRNA.28 Perez-Novo et al. confirmed that the con-
centrations of CysLTs and eosinophil cationic protein
(ECP) and the expression level of LTC4synthase
mRNA in ENP tissues are significantly higher than
those in tissues with sinusitis without polyps.29 From
this observation, we conclude that ENP tissues con-
tain and produce large amounts of CysLTs, and that
there is a close correlation between CysLT produc-
tion and eosinophil accumulation in ENP tissue.30
CysLTs have several inflammatory effects on eosino-
phils, which are not only activation, but also an effect
on trafficking and apoptosis inhibition.31-33
CysLT OVERPRODUCTION IN HUMAN
ANAPHYLAXIS
Anaphylaxis is a life-threatening generalized allergic
reaction that occurs when antigens bind to immuno-
globulin E on mast cells and basophiles causing the
release of inflammatory mediators.34,35 We focused
on the changes in inflammatory mediator concentra-
tions during anaphylactic reactions in our recent
study. We have demonstrated that anaphylaxis is as-
sociated with increased excretions of LTE4 and 9α, 11
β-PGF2 (Fig. 10),36,37 and a significant correlation be-
tween the concentrations of these two mediators.37
The observations suggest that mast cells may partici-
pate in the generation of CysLTs during the anaphy-
lactic reactions. The changes in mediator concentra-
tions may provide valuable information on therapeu-
Hyperleukotrieneuria in Asthma and Inflammation
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tic targets in anaphylaxis.
EOSINOPHILIC PNEUMONIA (EP) AND
CysLTs OVERPRODUCTION
Eosinophilic pneumonia (EP) is a diffuse infiltrative
lung disease characterized by alveolar and peripheral
airway eosinophilia.38-40 Although eosinophils pro-
duce cysteinyl leukotrienes (CysLTs) in large quanti-
ties, information on the relationship between CysLTs
and eosinophilic pneumonia (EP) is lacking. We dem-
onstrated that the urinary LTE4 concentration is sig-
nificantly higher in EP patients during acute exacer-
bation than in asthma patients with acute exacerba-
tion and healthy subjects (Fig. 11),41 and the concen-
tration significantly decreases in EP patients during
clinical remission. These findings suggest that
CysLTs production is closely associated with the
clinical conditions of EP patients. We also demon-
strated that the progression of eosinophilic pneumo-
nia is associated with elevated urinary leukotriene E4
and eosinophil-derived neurotoxin concentrations,
which may originate from eosinophil activation.41 The
leukotriene E4 concentration was correlated with the
level of diffusing capacity of the lung for carbon mon-
oxide during acute exacerbation.41 These findings
suggest that the monitoring of the leukotriene E4
concentration may aid in the management of eosino-
philic pneumonia patients.
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